Do you want to read an article? Please log in or register.
NTRK fusions in lung cancer: From biology to therapy
Lung, Respiratory and Thoracic Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Früh M, Panje CM, Reck M, Blackhall F, Califano R, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruysscher D, Putora PM
doi: 10.1016/j.lungcan.2020.03.024.
Endocrine and Neuroendocrine Tumors (NET)Lung, Respiratory and Thoracic Cancer
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions
Clin Cancer Res.
Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL, Fourie Zirkelbach J, Li Y, Liu J, Charlab R, Reyes Turcu F, Liang D, Ghosh S, Roscoe D, Philip R, Zack-Taylor A, Tang S, Kluetz PG, Beaver JA, Pazdur R, Theoret MR, Singh H
doi: 10.1158/1078-0432.CCR-20-3558.
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
ESMO Open
Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G
doi: 10.1016/j.esmoop.2021.100113
Lung, Respiratory and Thoracic Cancer
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer
Lung Cancer.
Berghmans T, Lievens Y, Aapro M, Baird AM, Beishon M, Calabrese F, Dégi C, Delgado Bolton RC, Gaga M, Lövey J, Luciani A, Pereira P, Prosch H, Saar M, Shackcloth M, Tabak-Houwaard G, Costa A, Poortmans P
doi: 10.1016/j.lungcan.2020.08.017.
Further Publications
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Ann Oncol.
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S
doi: 10.1093/annonc/mdz383.
Lung, Respiratory and Thoracic Cancer
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
J Clin Oncol
Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, Camidge DR, Arcila M, Ignatius Ou SH, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J
doi: 10.1200/JCO.20.03307
Lung, Respiratory and Thoracic Cancer
Overdiagnosis in lung cancer screening - estimates from the German Lung Cancer Screening Intervention Trial
Int J Cancer.
González Maldonado S, Motsch E, Trotter A, Kauczor HU, Heussel CP, Hermann S, Zeissig SR, Delorme S, Kaaks R
doi: 10.1002/ijc.33295.
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Clin Lung Cancer.
Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research
doi: 10.1016/
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.